Natalie Mount

Natalie Mount is an accomplished professional with extensive experience in the biotechnology and therapeutic sectors. Currently serving as a Venture Partner at Abingworth and Board Chair at Wugen, Natalie also holds the position of Independent Board Director at Rinri Therapeutics. Previously, Natalie was the Chief Executive Officer of Adaptate Biotherapeutics from its inception until its acquisition by Takeda, and served in various leadership roles including Chief Scientific Officer at GammaDelta Therapeutics and Chief Clinical Officer at Cell and Gene Therapy Catapult. With a strong background in clinical development at Pfizer, including roles as Acting Head of Clinical Research and Executive Director, Natalie's educational qualifications include a PhD in Biochemistry from UCL and a degree in Natural Sciences from the University of Cambridge.